Sevelamer reduces endothelial inflammatory response to advanced glycation end products

BACKGROUND: Advanced glycation end products (AGEs) have been related to the pathogenesis of cardiovascular diseases (CVD), chronic kidney disease (CKD) and diabetes mellitus. We sought to investigate the binding capacity of sevelamer to both AGEs and uremic serum in vitro and then test this pharmace...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Clin Kidney J
Päätekijät: Gregório, Paulo C, Favretto, Giane, Sassaki, Guilherme L, Cunha, Regiane S, Becker-Finco, Alessandra, Pecoits-Filho, Roberto, Souza, Wesley M, Barreto, Fellype C, Stinghen, Andréa E M
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2018
Aiheet:
CKD Complications
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5798142/
https://ncbi.nlm.nih.gov/pubmed/29423208
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ckj/sfx074
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia